Microbot Medical Inc
Suletud
1.85 -14.75
Ülevaade
Aktsiahinna muutus
24h
Min
1.73
Max
2.16
Sissetulek | 113K -3.5M |
|---|---|
Töötajad | 43 |
EBITDA | -561K -4.1M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +303.23% upside |
Järgmine tulemuste avaldamine | 19. mai 2026 |
|---|
Turukapital | -22M 147M |
|---|---|
Eelmine avamishind | 16.6 |
Eelmine sulgemishind | 1.85 |
Tehniline skoor
By Trading Central
Kindlus
Neutral Evidence
Microbot Medical Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Microbot Medical Inc Prognoos
Hinnasiht
By TipRanks
303.23% tõus
12 kuu keskmine prognoos
Keskmine 8.75 USD 303.23%
Kõrge 12 USD
Madal 5.5 USD
Põhineb 2 Wall Streeti analüütiku instrumendi Microbot Medical Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Microbot Medical Inc
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
